Initial Statement of Beneficial Ownership (3)
17 Avril 2023 - 10:17PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Georgianna Maule-Ffinch 2015 Trust |
2. Date of Event Requiring Statement (MM/DD/YYYY)
4/10/2023
|
3. Issuer Name and Ticker or Trading Symbol
Better Therapeutics, Inc. [BTTX]
|
(Last)
(First)
(Middle)
C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
SAN FRANCISCO, CA 94104
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 3636364 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | On April 6, 2023, the Issuer entered into a Securities Purchase Agreement with certain investors (the "PIPE Investors") in a private placement offering, pursuant to which the PIPE Investors agreed to purchase shares of Issuer common stock for $0.825 per share. As one of the PIPE Investors, the Reporting Person acquired 3,636,364 shares of Issuer common stock on April 10, 2023 for $0.825 per share. |
Remarks: Exhibit 24 - Power of Attorney |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Georgianna Maule-Ffinch 2015 Trust C/O BETTER THERAPEUTICS, INC. 548 MARKET STREET, #49404 SAN FRANCISCO, CA 94104 |
| X |
|
|
Signatures
|
/s/ Mark Heinen, Attorney-in-Fact for Georgianna Maule-Ffinch 2015 Trust | | 4/17/2023 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Mountain Crest Acquisiti... (NASDAQ:MCAD)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Mountain Crest Acquisiti... (NASDAQ:MCAD)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
Real-Time news about Mountain Crest Acquisition Corporation II (NASDAQ): 0 recent articles
Plus d'articles sur Better Therapeutics, Inc.